Valuation: Aquestive Therapeutics, Inc.

Market Cap 488M 436M 400M 364M 682M 46.22B 696M 4.78B 1.93B 24.4B 1.83B 1.79B 77.06B P/E 2026 *
-7.72x
P/E 2027 * -8.1x
Enterprise Value 410M 366M 336M 306M 573M 38.84B 585M 4.01B 1.62B 20.5B 1.54B 1.51B 64.75B EV / Sales 2026 *
8.04x
EV / Sales 2027 * 7.2x
Free-Float
89.21%
Yield 2026 *
-
Yield 2027 * -
1 day-4.76%
1 week-6.42%
Current month-4.50%
1 month-18.35%
3 months-1.98%
6 months-11.97%
Current year-42.49%
1 week 3.64
Extreme 3.635
4.29
1 month 3.64
Extreme 3.635
4.98
Current year 2.93
Extreme 2.93
6.59
1 year 2.93
Extreme 2.93
6.85
3 years 1.48
Extreme 1.48
7.55
5 years 0.62
Extreme 0.618
7.55
10 years 0.62
Extreme 0.618
20.7
Manager TitleAgeSince
Chief Executive Officer 50 2022-05-16
Director of Finance/CFO 67 2020-12-30
Compliance Officer - 2026-04-01
Director TitleAgeSince
Chairman 72 2024-03-31
Director/Board Member 60 2003-12-31
Director/Board Member 50 2022-05-16
Date Insider Type Main position Quantity % Market Cap. Importance
10/15/26 Sell

Chief Executive Officer

-25,000 0.0199%
10/15/26 Other

Director

0 0% -
9/15/26 Sell

Chief Executive Officer

-25,000 0.0199%
Change 5-day change 1-year change 3-year change Capi.($)
-4.76%-6.42%-42.76%+157.99% 488M
-0.84%+10.16%+57.17%+142.82% 1,263B
-1.34%+1.06%+44.49%+79.14% 658B
-2.51%+0.42%+35.84%+100.99% 521B
-1.54%+0.18%+53.06%+66.79% 391B
-0.49%+5.97%+80.63%+44.87% 369B
-1.69%+3.17%+32.18%+55.35% 307B
-0.72%+7.83%+12.10%+33.76% 290B
+0.10%+4.74%+57.18%+74.69% 252B
-0.26%+7.06%+39.20%+109.15% 212B
Average -1.40%+5.03%+36.91%+86.55% 426.24B
Weighted average by Cap. -1.11%+6.60%+48.49%+93.01%

Financials

2026 *2027 *
Net sales 51.04M 45.57M 41.82M 38.04M 71.32M 4.83B 72.74M 499M 201M 2.55B 192M 187M 8.06B 67.77M 60.5M 55.52M 50.51M 94.69M 6.42B 96.58M 663M 267M 3.39B 254M 249M 10.7B
Net income -62.87M -56.13M -51.51M -46.85M -87.84M -5.95B -89.59M -615M -248M -3.14B -236M -231M -9.92B -60.23M -53.77M -49.34M -44.89M -84.15M -5.7B -85.83M -589M -238M -3.01B -226M -221M -9.51B
Net Debt -78M -69.64M -63.9M -58.13M -109M -7.38B -111M -763M -308M -3.9B -293M -287M -12.31B -
Projected Income Statement - Annual - Aquestive Therapeutics, Inc.
Logo Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Employees
147
Date Price Change Volume
26-11-02 $3.685 -5.27% 1,914,084
26-10-30 $3.890 -3.71% 2,419,987
26-10-29 $4.040 -4.49% 2,018,392
26-10-28 $4.230 +3.93% 1,551,745
26-10-27 $4.070 +2.52% 1,325,306
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Aquestive Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.890USD
Average target price
9.333USD
Spread / Average Target
+139.93%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Aquestive Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. AQST Stock